Analyst Price Target is $13.33
▲ +36.19% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $13.33, with a high forecast of $18.00 and a low forecast of $8.00. The average price target represents a 36.19% upside from the last price of $9.79.
Current Consensus is
Moderate Buy
The current consensus among 7 investment analysts is to moderate buy stock in Arcutis Biotherapeutics. This rating has held steady since September 2023, when it changed from a Buy consensus rating.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More